Combining MCL-1 inhibition and CD37-directed chimeric antigen receptor T cells as an effective strategy to target T-cell lymphoma Summary Combining MCL-1 inhibition with CD37-directed CAR T-cell therapy shows promise for treating T-cell lymphoma. Read More
ICANS risk model in CD19 CAR-T therapy: insights from serum and CSF cytokine profiling Summary This study explores the predictive power of the Immune Cell-Associated Neurotoxicity Syndrome (ICANS) risk model in CD19 CAR-T therapy patients Read More
Endogenous T cell responses to fusion-derived neoantigens in pediatric acute leukemias Summary Pediatric acute leukemias, particularly those with fusion oncogenes, can generate unique neoantigens derived from the fusion point. Research has shown that the immune Read More
Efficacy and safety of immunosuppressive therapy versus cyclosporine combined with avatrombopag in older adults with severe aplastic anemia: a multicenter prospective study Summary A multicenter prospective study investigated the efficacy and safety of immunosuppressive therapy (Read More
The European Conference on Infections in Leukaemia (ECIL-10) guidelines for COVID-19 should take convalescent plasma into proper consideration Summary The upcoming ECIL-10 guidelines for COVID-19 management in leukemia patients should thoroughly evaluate the potential benefits Read More
Is immune effector cell-associated enterocolitis a CAR T-cell lymphoproliferative disorder? Summary Immune effector cell-associated enterocolitis (IEC-associated enterocolitis) can manifest after CAR T-cell therapy, presenting with gastrointestinal inflammation. While resembling graft-versus-host disease (GVHD), it’s often Read More
1 Million+ Views and Counting..!
It has been 7 years since it was launched in late July 2018, and it is moving forward. Appreciate all the respected visitors! Please share this site with your friends to push science forward and improve human health.
